Introducing: The AmoyDx® HANDLE Melanoma NGS Panel
The AmoyDx® HANDLE Melanoma NGS Panel is a Next-Generation Sequencing-based assay for the qualitative detection of SNVs and InDels in nine key melanoma genes.
Analyzing DNA from FFPE tissue with the AmoyDx® HANDLE Melanoma NGS Panel not only allows the analysis of common biomarkers, such as BRAF, but also the detection of mutations in two critical hotspot areas of the TERT promoter. On top of that, the fast and flexible HANDLE technology allows library preparation in only 5 hours with only one reaction tube per sample.
For more information about the AmoyDx® HANDLE Melanoma NGS Panel click here.
This product is for research use only (RUO).
Further topics
S3 guideline for prostate cancer was updated
In May 2024 the S3 guideline "Prostate Cancer" (version 7.0) was updated. For the first time it is recommended to sequence genes involved in homologous recombination repair (HRR), e. g. ATM, BRCA1/2, BRIP1, CDK12, CHEK2, FANCA, HDAC2 and PALB2, before initiating a systemic therapy for castration-resistant prostate cancer (mCRPC).
